KR100388605B1 - 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 - Google Patents
용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 Download PDFInfo
- Publication number
- KR100388605B1 KR100388605B1 KR10-2000-0032425A KR20000032425A KR100388605B1 KR 100388605 B1 KR100388605 B1 KR 100388605B1 KR 20000032425 A KR20000032425 A KR 20000032425A KR 100388605 B1 KR100388605 B1 KR 100388605B1
- Authority
- KR
- South Korea
- Prior art keywords
- itraconazole
- liquid composition
- weight
- acid
- parts
- Prior art date
Links
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title claims abstract description 92
- 229960004130 itraconazole Drugs 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 239000007788 liquid Substances 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000004090 dissolution Methods 0.000 claims abstract description 26
- 238000009472 formulation Methods 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 8
- 239000007901 soft capsule Substances 0.000 claims abstract description 7
- 239000007902 hard capsule Substances 0.000 claims abstract description 4
- 239000011259 mixed solution Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 13
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229940066429 octoxynol Drugs 0.000 claims description 3
- 229920002113 octoxynol Polymers 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000006193 liquid solution Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 235000011044 succinic acid Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 25
- 239000002245 particle Substances 0.000 description 12
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 10
- 238000003756 stirring Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 5
- 229940063138 sporanox Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 3
- BUILWQRVQTVUTH-UHFFFAOYSA-N butanoic acid;2-methoxyphenol Chemical compound CCCC(O)=O.COC1=CC=CC=C1O BUILWQRVQTVUTH-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012803 melt mixture Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008016 pharmaceutical coating Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
원료약품 | 중량(㎎) |
이트라코나졸 | 100 |
폴리에틸렌글리콜 400 | 250 |
디에틸렌글리콜 모노에틸에테르 | 400 |
구연산 | 250 |
전량 | 1,000 |
원료약품 | 중량(㎎) |
이트라코나졸 | 100 |
폴리에틸렌글리콜 400 | 250 |
디에틸렌글리콜 모노에틸에테르 | 400 |
말린산 | 250 |
전량 | 1,000 |
원료약품 | 중량(㎎) |
이트라코나졸 | 100 |
폴리에틸렌글리콜 400 | 250 |
디에틸렌글리콜 모노에틸에테르 | 400 |
구연산 | 240 |
부틸레이트 히드록시아니졸 | 10 |
전량 | 1,000 |
원료약품 | 중량(㎎) |
이트라코나졸 | 100 |
폴리에틸렌글리콜 400 | 250 |
디에틸렌글리콜 모노에틸에테르 | 400 |
구연산 | 240 |
히드록시프로필메틸셀룰로오스 | 10 |
전량 | 1,000 |
원료약품 | 중량(㎎) |
이트라코나졸 | 100 |
폴리에틸렌글리콜 400 | 250 |
디에틸렌글리콜 모노에틸에테르 | 400 |
구연산 | 240 |
폴리소르베이트(tween 80) | 10 |
전량 | 1,000 |
검체 | 용해도(㎍/㎖) |
이트라코나졸 원료 | 3.5 |
실시예 1 | 250 |
실시예 2 | 240 |
실시예 3 | 246 |
실시예 4 | 247 |
실시예 5 | 240 |
Cmax(ng/㎖) | AUC(ng/㎖·h) | |
실시예 1 | 7750±2149 | 92.51±18.66 |
시판제제(SPORANOX™) | 2670±2688 | 15.69±3.70 |
Claims (12)
- 이트라코나졸 1 중량부; 용해보조제 2∼3 중량부; 조성물의 pH를 1.0∼3.0으로 조정할 수 있는 pH 조정제 1∼3 중량부; 및 가용화제 3∼6 중량부의 혼합용해액으로 이루어진 이트라코나졸 액상 조성물.
- 제 1 항에 있어서,상기 pH 조정제는 조성물의 pH를 2.0±0.4 로 조정할 수 있는 양으로 사용되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 1 항에 있어서,상기 가용화제는 디에틸렌글리콜 모노에틸에테르, 벤질알코올, 글리세린, 옥톡시놀, 프로필렌글리콜, 프로필렌카보네이트, 폴리에틸렌글리콜 및 이들의 혼합물로 구성된 군으로부터 선택되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 1 항에 있어서,상기 용해보조제는 디에틸렌글리콜 모노에틸에테르, 벤질알코올, 글리세린, 옥톡시놀, 프로필렌글리콜, 프로필렌카보네이트, 폴리에틸렌글리콜 및 이들의 혼합물로 구성된 군으로부터 선택되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 1 항에 있어서,상기 pH 조정제는 염산, 구연산, 말린산, 주석산, 아스코르빈산, 젖산, 사과산, 호박산 및 이들의 혼합물로 구성된 군으로부터 선택되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 1 항에 있어서,상기 조성물은, 이트라코나졸의 용해도를 높이고 제제의 안정화를 위하여 물, 항산화제, 계면활성제 및 고분자화합물로 이루어진 군으로부터 선택된 하나 이상의 첨가제 0.1∼1 중량부를 더 포함하는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 6 항에 있어서,상기 항산화제는 아스코르빈산, 푸마르산, 말린산, 부틸레이트 히드록시아니졸 및 이들의 혼합물로 이루어진 군으로부터 선택되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 6 항에 있어서,상기 계면활성제는, 폴리에틸렌 경화피마자유, 폴리에틸렌글리콜 카프리레이트/카프레이트, 글리세린지방산에스텔 및 폴리소르베이트 및 이들의 혼합물로 이루어진 군으로부터 선택되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- 제 6 항에 있어서,상기 고분자화합물은 폴리비닐피롤리돈, 히드록시프로필메틸셀룰로오스 (HPMC) 및 히드록시프로필셀룰로오스(HPC) 중에서 선택되는 것을 특징으로 하는 이트라코나졸 액상 조성물.
- (a) 이트라코나졸 1 중량부에 용해보조제 2∼3 중량부를 혼합한 후 열을 가해 용해시키고;(b) 별도로 조성물의 pH를 1.0∼3.0으로 조정할 수 있는 pH 조정제 1∼3 중량부를 가용화제 3∼6 중량부에 용해시킨 후;(c) (b)를 (a)의 이트라코나졸 용해액에 혼합하는 것을 특징으로 하는 이트라코나졸 액상 조성물의 제조방법
- 통상의 약제학적 방법을 사용하여 제 1 항의 이트라코나졸 액상 조성물을 치료학적 유효량으로 포함시킨 이트라코나졸 제제.
- 제 11 항에 있어서,상기 제제는 연질캅셀제, 경질캅셀제, 내용액제, 외용액제 중 어느 하나의 제형을 갖는 것임을 특징으로 하는 이트라코나졸 제제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0032425A KR100388605B1 (ko) | 2000-06-13 | 2000-06-13 | 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0032425A KR100388605B1 (ko) | 2000-06-13 | 2000-06-13 | 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010111762A KR20010111762A (ko) | 2001-12-20 |
KR100388605B1 true KR100388605B1 (ko) | 2003-06-25 |
Family
ID=45932640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0032425A KR100388605B1 (ko) | 2000-06-13 | 2000-06-13 | 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100388605B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012039768A2 (en) * | 2010-09-24 | 2012-03-29 | Texas Southern University | Itraconazole formulations |
KR102376314B1 (ko) * | 2021-04-09 | 2022-03-18 | 주식회사 바이오빌리프 | 이트라코나졸을 포함하는 용액 형태의 국소 투여용 약학 조성물 및 이의 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR940703651A (ko) * | 1992-02-12 | 1994-12-12 | 루크체티 지오반니 | 리포솜 이트라코나졸 제제[liposomal itraconazole formula-tions] |
WO1995031178A1 (en) * | 1994-05-18 | 1995-11-23 | Janssen Pharmaceutica N.V. | Mucoadhesive emulsions containing cyclodextrin |
KR20000032511A (ko) * | 1998-11-16 | 2000-06-15 | 양주환 | 이트라코나졸 등의 항진균제를 함유하는 연질캅셀제 |
KR20000059789A (ko) * | 1999-03-09 | 2000-10-05 | 민경윤 | 항진균제의 외용 약제 조성물 및 이의 제조방법 |
-
2000
- 2000-06-13 KR KR10-2000-0032425A patent/KR100388605B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR940703651A (ko) * | 1992-02-12 | 1994-12-12 | 루크체티 지오반니 | 리포솜 이트라코나졸 제제[liposomal itraconazole formula-tions] |
WO1995031178A1 (en) * | 1994-05-18 | 1995-11-23 | Janssen Pharmaceutica N.V. | Mucoadhesive emulsions containing cyclodextrin |
KR20000032511A (ko) * | 1998-11-16 | 2000-06-15 | 양주환 | 이트라코나졸 등의 항진균제를 함유하는 연질캅셀제 |
KR20000059789A (ko) * | 1999-03-09 | 2000-10-05 | 민경윤 | 항진균제의 외용 약제 조성물 및 이의 제조방법 |
Non-Patent Citations (1)
Title |
---|
논문(1996.11.1) * |
Also Published As
Publication number | Publication date |
---|---|
KR20010111762A (ko) | 2001-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100425755B1 (ko) | 이트라코나졸을 함유하는 조성물 및 그 제조방법 | |
EP2451438B1 (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
EP1474172B1 (en) | Pharmaceutical compositions for hepatitis c viral protease inhibitors | |
EP1239831B1 (en) | Improved pharmaceutical compositions for poorly soluble drugs | |
KR100694667B1 (ko) | 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 | |
RU2314811C2 (ru) | Пероральная композиция твердого раствора малорастворимого в воде активного вещества | |
JP2003300907A (ja) | 抗真菌製剤、及びその製造方法ならびに使用 | |
KR100381834B1 (ko) | 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법 | |
US20020147232A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
AU2006257428B2 (en) | Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin | |
JPH03500651A (ja) | トコフェロールを基体とした薬剤系 | |
KR100388605B1 (ko) | 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 | |
DE10392718T5 (de) | Pharmazeutische Formulierung in einem Medikamentenfreisetzungssystem und Verfahren zur Herstellung derselben | |
KR20240024979A (ko) | 난용성 약물의 삼투압 펌프 제어 방출 정제 및 그의 제조방법 | |
EP3854384A1 (en) | Pharmaceutical formulation comprising abiraterone acetate | |
CA2409950A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
KR100479367B1 (ko) | 이트라코나졸을 포함하는 경구투여용 항진균제 조성물 | |
US20070148240A1 (en) | Oral formulation containing itraconazole and methods for manufacturing and using the same | |
KR100588810B1 (ko) | 글리메피리드를 가용화시켜 투명 내용액으로 함유한연질캅셀제 | |
KR100432949B1 (ko) | 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법 | |
KR20230024389A (ko) | 우티델론의 고체 경구용 제제 | |
KR20230122484A (ko) | 고함량의 티카그렐러를 포함하는 고효율 나노지질담체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
US20240091217A1 (en) | Stable pharmaceutical oral liquid formulation of an antispasmodic agent | |
KR100790954B1 (ko) | 이트라코나졸 함유 젤라틴 초미세 미립구 | |
KR100441745B1 (ko) | 이트라코나졸의 경구투여용 조성물과 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130610 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140609 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150608 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20160610 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170609 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180607 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20190605 Year of fee payment: 17 |